Bellicum Pharmaceuticals Overview
- Founded
-
2004
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
BLCM
- Share Price
-
$1.10
- (As of Wednesday Closing)
Bellicum Pharmaceuticals General Information
Description
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
- 3730 Kirby Drive
- Suite 1200
- Houston, TX 77098
- United States
+1 (281) 000-0000
Bellicum Pharmaceuticals Timeline
Bellicum Pharmaceuticals Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.10 | $1.10 | $1.00 - $3.00 | $9.5M | 8.61M | 21.1K | -$0.18 |
Bellicum Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (11,488) | 11,283 | 18,768 | 27,231 |
| Revenue | 5,500 | 6,200 | 500 | 7,143 |
| EBITDA | (7,797) | (9,595) | (3,576) | (101,042) |
| Net Income | (7,799) | (9,705) | (7,722) | (112,477) |
| Total Assets | 36,604 | 49,143 | 40,584 | 116,250 |
| Total Debt | 0 | 0 | 1,169 | 38,035 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Bellicum Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bellicum Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Bellicum Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherap
Drug Discovery
Houston, TX
7
As of 2021
00000
000000000
00000
0000 0
lore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000 000000000
Cambridge, MA
00
As of 0000
00000
00000000
00000
00000
psum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolo
0000000000000
Waltham, MA
000
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
Bellicum Pharmaceuticals Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | Waltham, MA | 000 | 00000 | 00000000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Houston, TX | 00 | 00000 | 000000&0 | 00000 |
| 0000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
Bellicum Pharmaceuticals Patents
Bellicum Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020327994-A1 | Improved formulations for immune cells | Pending | 12-Aug-2019 | 000000000 | |
| EP-4013513-A1 | Improved formulations for immune cells | Pending | 12-Aug-2019 | 000000000 | |
| CA-3147289-A1 | Improved formulations for immune cells | Pending | 12-Aug-2019 | 000000000 | |
| US-20220273717-A1 | Improved formulations for immune cells | Pending | 12-Aug-2019 | 0000000000 | |
| AU-2019397048-A1 | Psca car-t cells | Pending | 13-Dec-2018 | A61K35/17 |
Bellicum Pharmaceuticals Executive Team (17)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Richard Fair | Chief Executive Officer & Board Member | ||
| Charity Scripture | Executive |
Bellicum Pharmaceuticals Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| James Daly | Self | Board Member | 000 0000 |
| Jon Stonehouse | Self | Chairman & Board Member | 000 0000 |
| Judith Klimovsky | Self | Board Member | 000 0000 |
| Reid Huber Ph.D | Self | Board Member | 000 0000 |
| Richard Fair | Bellicum Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
Bellicum Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
